Investigator-initiated phase I/II or phase II immunotherapy trials led by academic researchers to drive clinical impact, uncover mechanisms of response/resistance, and develop/validate predictive biomarkers. CRI may provide strategic input on trial design and encourages data sharing (e.g., CRI iATLAS).
Eligibility Criteria:
-
Principal Investigator of the proposed study at a non-profit medical school or research center (U.S. or abroad).
-
No citizenship restrictions.
-
Not eligible: research at for-profit institutions.
-
Chordoma-focused proposals are welcomed and may be co-funded with the Chordoma Foundation (models and banked tumor samples available).
Funding Details:
-
Up to USD 1,000,000 per trial.
-
Supports investigator salary, patient costs, supplies, correlative assays, and data analyses.
-
Milestone-based payments to ensure progress and completion.
-
Indirect costs up to 10% in addition to the award.
Deadline:
-
Protocol Concept deadline: December 1, 2025 (11:59 p.m. Eastern Time).
-
Invited Full Proposal deadline: April 4, 2026 (11:59 p.m. Eastern Time).
-
If a deadline falls on a weekend/holiday, submissions are accepted the following workday.
Where to go for further information: